AIM: To evaluate virological response to telaprevir or boceprevir in combination with pegylated interferon and ribavirin and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus (HCV-HIV) coinfected patients in a real life setting. METHODS: Patients with HCV genotype 1-HIV coinfection followed in Nice University Hospital internal medicine and infectious diseases departments who initiated treatment including pegylated interferon and ribavirin (PegIFN/RBV) + telaprevir or boceprevir, according to standard treatment protocols, between August 2011 and October 2013 entered this observational study. Patient data were extracted from an electronic database (Nadis(®)). Liver fibrosis was measured by elastometry (Fibroscan(®)) with the following cut-off values: F0-F1: < 7.1 kPa, F2: 7.1-9.5 kPa, F3: 9.5-14.5 kPa, F4: ≥ 14.5 kPa. The proportion of patients with sustained virological response (SVR) twelve weeks after completing treatment, frequency and type of adverse events, and NS3/4A protease inhibitor mutations were described. RESULTS: Forty-one patients were included: 13 (31.7%) patients were HCV-treatment naïve, 22 (53.7%) had advanced liver fibrosis or cirrhosis (Fibroscan stage F3 and F4); none had decompensated cirrhosis or hepatocellular carcinoma; all were receiving antiretroviral treatment, consisting for most them (83%) in either a nucleoside reverse-transcriptase inhibitor/protease inhibitor or/integrase inhibitor combination; all patients had undetectable HIV-RNA. One patient was lost to follow-up. SVR was achieved by 52.5% of patients. Five patients experienced virological failure during treatment and four relapsed. Seven discontinued treatment due to adverse events. Main adverse events included severe anemia (88%) and rash (25%). NS3/4A protease mutations were analyzed at baseline and at the time of virological failure in the 9 patients experiencing non-response, breakthrough or relapse. No baseline resistance mutation could predict resistance to HCV protease inhibitor-based treatment. CONCLUSION: Telaprevir and boceprevir retain their place among potential treatment strategies in HIV-HCV coinfected patients including those with advanced compensated liver disease and who failed previous PegIFN/RBV therapy.
AIM: To evaluate virological response to telaprevir or boceprevir in combination with pegylated interferon and ribavirin and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus (HCV-HIV) coinfectedpatients in a real life setting. METHODS:Patients with HCV genotype 1-HIV coinfection followed in Nice University Hospital internal medicine and infectious diseases departments who initiated treatment including pegylated interferon and ribavirin (PegIFN/RBV) + telaprevir or boceprevir, according to standard treatment protocols, between August 2011 and October 2013 entered this observational study. Patient data were extracted from an electronic database (Nadis(®)). Liver fibrosis was measured by elastometry (Fibroscan(®)) with the following cut-off values: F0-F1: < 7.1 kPa, F2: 7.1-9.5 kPa, F3: 9.5-14.5 kPa, F4: ≥ 14.5 kPa. The proportion of patients with sustained virological response (SVR) twelve weeks after completing treatment, frequency and type of adverse events, and NS3/4A protease inhibitor mutations were described. RESULTS: Forty-one patients were included: 13 (31.7%) patients were HCV-treatment naïve, 22 (53.7%) had advanced liver fibrosis or cirrhosis (Fibroscan stage F3 and F4); none had decompensated cirrhosis or hepatocellular carcinoma; all were receiving antiretroviral treatment, consisting for most them (83%) in either a nucleoside reverse-transcriptase inhibitor/protease inhibitor or/integrase inhibitor combination; all patients had undetectable HIV-RNA. One patient was lost to follow-up. SVR was achieved by 52.5% of patients. Five patients experienced virological failure during treatment and four relapsed. Seven discontinued treatment due to adverse events. Main adverse events included severe anemia (88%) and rash (25%). NS3/4A protease mutations were analyzed at baseline and at the time of virological failure in the 9 patients experiencing non-response, breakthrough or relapse. No baseline resistance mutation could predict resistance to HCV protease inhibitor-based treatment. CONCLUSION:Telaprevir and boceprevir retain their place among potential treatment strategies in HIV-HCV coinfectedpatients including those with advanced compensated liver disease and who failed previous PegIFN/RBV therapy.
Authors: Sophie Vallet; Florent Viron; Cecile Henquell; Helene Le Guillou-Guillemette; Giséle Lagathu; Florence Abravanel; Pascale Trimoulet; Patrick Soussan; Evelyne Schvoerer; Arielle Rosenberg; Stephanie Gouriou; Philippe Colson; Jacques Izopet; Christopher Payan Journal: Antivir Ther Date: 2011
Authors: Sarah Aherfi; Caroline Solas; Anne Motte; Jacques Moreau; Patrick Borentain; Saadia Mokhtari; Danielle Botta-Fridlund; Catherine Dhiver; Isabelle Portal; Jean-Marie Ruiz; Isabelle Ravaux; Sylvie Bregigeon; Isabelle Poizot-Martin; Andreas Stein; René Gérolami; Philippe Brouqui; Catherine Tamalet; Philippe Colson Journal: J Med Virol Date: 2014-07-23 Impact factor: 2.327
Authors: Pascal Pugliese; Lise Cuzin; André Cabié; Isabelle Poizot-Martin; Clotilde Allavena; Claudine Duvivier; Myriam El Guedj; Xavier de la Tribonnière; M A Valantin; P Dellamonica Journal: HIV Med Date: 2009-05-19 Impact factor: 3.180
Authors: James C Sullivan; Sandra De Meyer; Doug J Bartels; Inge Dierynck; Eileen Z Zhang; Joan Spanks; Ann M Tigges; Anne Ghys; Jennifer Dorrian; Nathalie Adda; Emily C Martin; Maria Beumont; Ira M Jacobson; Kenneth E Sherman; Stefan Zeuzem; Gaston Picchio; Tara L Kieffer Journal: Clin Infect Dis Date: 2013-04-10 Impact factor: 9.079
Authors: Mariantonietta Di Stefano; Mona H Ismail; Thomas Leitner; Giuseppina Faleo; Saada A Elmnan Adem; Mohamed O M E Elamin; Obeidi Eltreifi; Marwan J Alwazzeh; Jose R Fiore; Teresa A Santantonio Journal: Viruses Date: 2021-09-14 Impact factor: 5.818